Type 2 Diabetes Mellitus
Conditions
Keywords
saxagliptin, endothelial progenitor cell, flow-mediated dilation
Brief summary
In this study, the investigators aim to investigate whether saxagliptin modulate endothelial progenitor cells number and flow-mediated dilation in newly diagnosed, treatment-naive type 2 diabetic patients.
Interventions
DRUGsaxagliptin
5mg per day for 12 weeks
DRUGMetformin
1500mg per day for 12 weeks
Sponsors
Chinese Medical Association
Shanghai Zhongshan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* newly diagnosed type 2 diabetics (diagnosis were made according to the American Diabetes Association Guideline \[19\] ), treatment naive, age 30-75, hemoglobin A1c (HbA1c) ≥6.5%, fasting c-peptide \>1.0ng/L
Exclusion criteria
* pregnancy or lactation, smoker, acute disease or infection, chronic renal disease (estimated glomerular filtration rate \<60 mL/min/1.73m2), live enzymes 3 times above the normal range, positive islet autoantibody, fasting c-peptide \<1.0ng/L, severe hypertriglyceridemia (triglyceride \>5.6mmol/L), cardiovascular events or surgery within 3 months, taking glucocorticoid, history of acute or chronic pancreatitis, pancreatic tumor, severe cardiac or pneumonic disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| endothelial progenitor cell | 12weeks |
| flow-mediated dilation | 12weeks |
Secondary
| Measure | Time frame |
|---|---|
| 2 hour postprandial blood glucose | 12weeks |
| HbA1c | 12weeks |
| renal function test | 12weeks |
| liver function test | 12weeks |
| fasting blood glucose | 12weeks |
Countries
China
Outcome results
None listed